List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3764808/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Predictors of Hospitalization and Superinfection in Viral Respiratory Tract Infections Between Influenza and Paramyxoviruses: The SUPERFLUOUS Study. Journal of Infectious Diseases, 2022, 226, 1027-1035.	4.0	4
2	Native bone and joint infections caused by extended-spectrum β-lactamase-producing Enterobacterales: experience of a reference centre in the Greater Paris area. International Journal of Antimicrobial Agents, 2022, 59, 106497.	2.5	2
3	Modeling the omicron wave in France in early 2022: Balancing herd immunity with protecting the most vulnerable. Journal of Travel Medicine, 2022, , .	3.0	6
4	Population Pharmacokinetics of Hydroxychloroquine and 3 Metabolites in COVID-19 Patients and Pharmacokinetic/Pharmacodynamic Application. Pharmaceuticals, 2022, 15, 256.	3.8	3
5	Superinfection is associated with short-term outcome and mortality in viral respiratory tract infections during the fall-winter seasons 2016-2018 in the Greater Paris area: the SUPERFLUOUS study. International Journal of Infectious Diseases, 2022, 119, 217-224.	3.3	1
6	Cross-sectional study on COVID-19 vaccine hesitancy and determinants in healthcare students: interdisciplinary trainings on vaccination are needed. BMC Medical Education, 2022, 22, 299.	2.4	17
7	Esophageal brucellosis? Straight to the goat. International Journal of Infectious Diseases, 2022, 122, 276-278.	3.3	0
8	Monkeypox 2022 outbreak: cases with exclusive genital lesions. Journal of Travel Medicine, 2022, 29, .	3.0	42
9	Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients. European Journal of Clinical Pharmacology, 2021, 77, 389-397.	1.9	15
10	'Post-COVID-19 chronic symptoms' – Author's reply. Clinical Microbiology and Infection, 2021, 27, 495-496.	6.0	5
11	Eosinopenia in COVID-19: What we missed so far?. Journal of Microbiology, Immunology and Infection, 2021, 54, 1006-1007.	3.1	5
12	†Blue toes' following vaccination with the BNT162b2 mRNA COVID-19 vaccine. Journal of Travel Medicine, 2021, 28, .	3.0	29
13	Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. Lancet, The, 2021, 397, 1195-1203.	13.7	82
14	The first wave of COVID-19 in hospital staff members of a tertiary care hospital in the greater Paris area: A surveillance and risk factors study. International Journal of Infectious Diseases, 2021, 105, 172-179.	3.3	13
15	SARS-CoV-2 reinfections among hospital staff in the greater Paris area. Journal of Travel Medicine, 2021, 28, .	3.0	6
16	Treatment of bone and joint infections by ceftazidime/avibactam and ceftolozane/tazobactam: a cohort study. Journal of Global Antimicrobial Resistance, 2021, 25, 282-286.	2.2	7
17	Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study. International Journal of Antimicrobial Agents, 2021, 58, 106361.	2.5	13
18	Battlefield Medicine. Inference, 2021, 6, .	0.0	0

#	Article	IF	CITATIONS
19	Médecine de Catastrophe. Inference, 2021, 6, .	0.0	0
20	Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia. JAMA Network Open, 2021, 4, e2129566.	5.9	10
21	Persistent eosinopenia is associated with in-hospital mortality among older patients: unexpected prognostic value of a revisited biomarker. BMC Geriatrics, 2021, 21, 557.	2.7	5
22	Management and characteristics of patients suffering from <i>Clostridiodes difficile</i> infection in primary care. European Journal of General Practice, 2021, 27, 320-325.	2.0	0
23	No further delays in offering booster doses in countries experiencing a major resurgence of COVID-19. Journal of Travel Medicine, 2021, 28, .	3.0	2
24	Weekly Sequential Antibioprophylaxis for Recurrent Urinary Tract Infections Among Patients With Neurogenic Bladder: A Randomized Controlled Trial. Clinical Infectious Diseases, 2020, 71, 3128-3135.	5.8	16
25	Successful treatment of meningococcal bacteremia using oral doxycycline: A case report. International Journal of Infectious Diseases, 2020, 92, 78-80.	3.3	4
26	Clinical Cutaneous Features of Patients Infected With SARS-CoV-2 Hospitalized for Pneumonia: A Cross-sectional Study. Open Forum Infectious Diseases, 2020, 7, ofaa394.	0.9	10
27	Case series of carbapenemase-producing Enterobacteriaceae osteomyelitis: Feel it in your bones. Journal of Global Antimicrobial Resistance, 2020, 23, 74-78.	2.2	8
28	Post–COVID-19 chronic symptoms: a postinfectious entity?. Clinical Microbiology and Infection, 2020, 26, 1448-1449.	6.0	126
29	Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time. International Journal of Antimicrobial Agents, 2020, 56, 106129.	2.5	13
30	Testicular pain associated with clear fluid meningitis: How many cases of Toscana virus are we missing?. International Journal of Infectious Diseases, 2020, 93, 198-200.	3.3	2
31	Fluoroquinolone-induced motor neuron hyperexcitability. Revue Neurologique, 2020, 176, 296-298.	1.5	1
32	French national cohort of first use of dalbavancin: A high proportion of off-label use. International Journal of Antimicrobial Agents, 2019, 54, 668-672.	2.5	56
33	Eosinopenia as a marker of diagnosis and prognostic to distinguish bacterial from aseptic meningitis in pediatrics. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1821-1827.	2.9	10
34	All eyes on him: Argyll Robertson pupil in late syphilis. International Journal of Infectious Diseases, 2019, 83, 1-2.	3.3	0
35	Evaluation in general practice of the patient's feelings about a recent hospitalization and isolation for a multidrug-resistant infection. American Journal of Infection Control, 2019, 47, 1077-1082.	2.3	9
36	Tubercular splenic abscesses: A rare entity sometimes hard to sterilize. International Journal of Infectious Diseases, 2019, 82, 18-20.	3.3	0

#	Article	IF	CITATIONS
37	Fifty shades of graft: How to improve the efficacy of faecal microbiota transplantation for decolonization of antibiotic-resistant bacteria. International Journal of Antimicrobial Agents, 2019, 53, 553-556.	2.5	11
38	Interest of Eosinophil Count in Bacterial Infections to Predict Antimicrobial Therapy Efficacy. JAMA Surgery, 2019, 154, 464.	4.3	1
39	Efficacy of cotrimoxazole (Sulfamethoxazole-Trimethoprim) as a salvage therapy for the treatment of bone and joint infections (BJIs). PLoS ONE, 2019, 14, e0224106.	2.5	7
40	Fecal microbiota transplantation to eradicate vancomycin-resistant enterococci colonization in case of an outbreak. Médecine Et Maladies Infectieuses, 2019, 49, 214-218.	5.0	21
41	Title is missing!. , 2019, 14, e0224106.		0
42	Title is missing!. , 2019, 14, e0224106.		0
43	Title is missing!. , 2019, 14, e0224106.		0
44	Title is missing!. , 2019, 14, e0224106.		0
45	Title is missing!. , 2019, 14, e0224106.		0
46	Title is missing!. , 2019, 14, e0224106.		0
47	Title is missing!. , 2019, 14, e0224106.		0
48	Title is missing!. , 2019, 14, e0224106.		0
49	Clearance of carbapenem-resistant Enterobacteriaceae vs vancomycin-resistant enterococci carriage after faecal microbiota transplant: a prospective comparative study. Journal of Hospital Infection, 2018, 99, 481-486.	2.9	58
50	Comment on: High levels of susceptibility to new and older antibiotics in Neisseria gonorrhoeae isolates from Saskatchewan (2003–15): time to consider point-of-care or molecular testing for precision treatment?. Journal of Antimicrobial Chemotherapy, 2018, 73, 828-829.	3.0	1
51	Case of femoral pseudarthrosis due to <i>Scedosporium apiospermum</i> in an immunocompetent patient with successful conservative treatment and review of literature. Mycoses, 2018, 61, 400-409.	4.0	4
52	Interest in the monitoring of eosinophil count as a marker of the response to antimicrobial therapy: In response to Karakonstantis and Dimitra. International Journal of Infectious Diseases, 2018, 66, 145-146.	3.3	1
53	Back to the Future with the Use of Penicillin in Penicillin-Susceptible Staphylococcus aureus (PSSA) Bacteremia. American Journal of Medicine, 2018, 131, e155.	1.5	4
54	Cost effectiveness of pneumococcal urinary antigen in Emergency Department: a pragmatic real-life study. Internal and Emergency Medicine, 2018, 13, 69-73.	2.0	9

#	Article	IF	CITATIONS
55	Noncarbapenem ß-Lactams for the Treatment of Extended-Spectrum ß-Lactamase Infections: What Are the Remaining Drugs Outside the United States?. Clinical Infectious Diseases, 2018, 66, 316-316.	5.8	0
56	Factors associated with bacteraemia due to multidrug-resistant organisms among bacteraemic patients with multidrug-resistant organism carriage: a case control study. Antimicrobial Resistance and Infection Control, 2018, 7, 116.	4.1	15
57	Antibiotic prophylaxis approaches for urinary tract infections. Lancet Infectious Diseases, The, 2018, 18, 1065.	9.1	2
58	Extended-Spectrum Beta-Lactamase (ESBL)-Producing <i>Escherichia coli</i> versus <i>Klebsiella pneumoniae:</i> Does type of germ really matter?. Infection Control and Hospital Epidemiology, 2018, 39, 1137-1138.	1.8	3
59	Re: â€~Are third-generation cephalosporins associated with a better prognosis than amoxicillin-clavulanate in patients hospitalized in the medical ward for community-onset pneumonia?' by Batard, et al Clinical Microbiology and Infection, 2018, 24, 1222-1223.	6.0	1
60	Germs of thrones - spontaneous decolonization of Carbapenem-Resistant Enterobacteriaceae (CRE) and Vancomycin-Resistant Enterococci (VRE) in Western Europe: is this myth or reality?. Antimicrobial Resistance and Infection Control, 2018, 7, 100.	4.1	27
61	Implementation of a simple innovative system for postprescription antibiotic review based on computerized tools with shared access. Journal of Hospital Infection, 2017, 95, 312-317.	2.9	4
62	Is faecal microbiota transplantation an option to eradicate highly drug-resistant enteric bacteria carriage?. Journal of Hospital Infection, 2017, 95, 433-437.	2.9	75
63	Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2017, 49, 782-783.	2.5	40
64	Ceftolozane/tazobactam for febrile UTI due to multidrug-resistant Pseudomonas aeruginosa in a patient with neurogenic bladder. Spinal Cord Series and Cases, 2017, 3, 17019.	0.6	3
65	Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	124
66	Impact of faecal microbiota transplantation to eradicate vancomycin-resistant enterococci (VRE) colonization in humans. Journal of Infection, 2017, 75, 376-377.	3.3	10
67	Fecal Microbiota Transplantation Is a New Effective Weapon to Fight Multidrug-Resistant Bacteria, but Harmonization and More Data Are Needed. Clinical Infectious Diseases, 2017, 65, 1425-1426.	5.8	2
68	Repurposing an old drug: aztreonam as a new treatment strategy for gonorrhoea. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw589.	3.0	8
69	Oral Teicoplanin as an Alternative First-Line Regimen in Clostridium difficile Infection in Elderly Patients: A Case Series. Clinical Drug Investigation, 2017, 37, 699-703.	2.2	10
70	Is 5Âdays of oral fluoroquinolone enough for acute uncomplicated pyelonephritis? The DTP randomized trial. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 1443-1448.	2.9	25
71	Outcome of bloodstream infections among spinal cord injury patients and impact of multidrug-resistant organisms. Spinal Cord, 2017, 55, 148-154.	1.9	9
72	Interest of the Chosen Drug for Pyelonephritis: Does Size Matter?. American Journal of Medicine, 2017, 130, e471.	1.5	1

#	Article	IF	CITATIONS
73	Contribution of echocardiography in the diagnosis of definitive infective endocarditis: the infectious disease specialist's point of view. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 2329-2334.	2.9	3
74	Breast abscess due to Bacillus Calmette-Guérin. International Journal of Infectious Diseases, 2017, 59, 137-138.	3.3	1
75	Impact of an antimicrobial stewardship programme to optimize antimicrobial use for outpatients at an emergency department. Journal of Hospital Infection, 2017, 97, 288-293.	2.9	30
76	Monotherapy of ceftazidime–avibactam and ceftolozane–tazobactam: two effective antimicrobial agents against multidrug-resistant organisms except for NDM-1 isolates. International Journal of Infectious Diseases, 2017, 62, 124-125.	3.3	4
77	Reinforcement of an antimicrobial stewardship task force aims at a better use of antibiotics of last resort: the COLITIFOS study. International Journal of Antimicrobial Agents, 2017, 50, 142-147.	2.5	12
78	Changes in eosinophil count during bacterial infection: revisiting an old marker to assess the efficacy of antimicrobial therapy. International Journal of Infectious Diseases, 2017, 61, 62-66.	3.3	33
79	Efficacy of the switch to oral antibiotics in the treatment of non- Staphylococcus aureus infective endocarditis in non-severely ill patients. Clinical Microbiology and Infection, 2017, 23, 124-125.	6.0	4
80	Severe neutropenia revealing a rare presentation of dengue fever: a case report. BMC Research Notes, 2017, 10, 415.	1.4	4
81	Impact of Anti-Inflammatory Drugs on Pyogenic Vertebral Osteomyelitis: A Prospective Cohort Study. International Journal of Rheumatology, 2016, 2016, 1-4.	1.6	2
82	Phenol-Soluble Modulins Contribute to Early Sepsis Dissemination Not Late Local USA300-Osteomyelitis Severity in Rabbits. PLoS ONE, 2016, 11, e0157133.	2.5	17
83	Community-acquired Clostridium difficile infections in emergency departments. Médecine Et Maladies Infectieuses, 2016, 46, 372-379.	5.0	2
84	True incidence of tigecycline-induced pancreatitis: how many cases are we missing?. Journal of Antimicrobial Chemotherapy, 2016, 71, 2994-2995.	3.0	13
85	High rates of off-label use in antibiotic prescriptions in a context of dramatic resistance increase: a prospective study in a tertiary hospital. International Journal of Antimicrobial Agents, 2016, 47, 490-494.	2.5	19
86	Why should 1 gram of ceftriaxone monotherapy be considered as a therapeutic option in gonococcal sexually transmitted diseases?. Clinical Microbiology and Infection, 2016, 22, 903-904.	6.0	2
87	Is oral pristinamycin effective for the treatment of resistant Gram-positive infections as a relay after initial parenteral antimicrobial therapy?. International Journal of Antimicrobial Agents, 2016, 48, 574-575.	2.5	0
88	Blood stream infections due to multidrug-resistant organisms among spinal cord-injured patients, epidemiology over 16 years and associated risks: a comparative study. Spinal Cord, 2016, 54, 720-725.	1.9	22
89	Hip joint infections caused by multidrug-resistant Enterobacterales among patients with spinal cord injury: experience of a reference center in the Greater Paris area. Open Forum Infectious Diseases, 0, , .	0.9	1